Ophthalmology

Mount Sinai Boards of Trustees Announce Updated Leadership Structure

Monday, September 20, 2021 - 4:40pm

NEW YORK, Sept. 20, 2021 /PRNewswire-PRWeb/ --The Mount Sinai Boards of Trustees today announced leadership updates that will position the Mount Sinai Health System for future challenges and opportunities.

Key Points: 
  • NEW YORK, Sept. 20, 2021 /PRNewswire-PRWeb/ --The Mount Sinai Boards of Trustees today announced leadership updates that will position the Mount Sinai Health System for future challenges and opportunities.
  • Dr. Davis, who became President and Chief Executive Officer of The Mount Sinai Medical Center in 2003 and of the Mount Sinai Health System upon its formation in 2013, has successfully led Mount Sinai through an era of unprecedented growth and change, including the creation of the multi-hospital Health System and the transformation of care delivery.
  • Davis and Charney will continue to provide their visionary guidance, counsel, and leadership acumen," said Richard A. Friedman and James S. Tisch, Co-Chairmen of the Boards of Trustees of the Mount Sinai Health System.
  • 1 in New York and top five globally, and Mount Sinai Morningside as top 20 globally, and "The World's Best Specialized Hospitals" ranks Mount Sinai Heart as No.

ZEISS Introduces a Series of Major Innovations and Industry-First Software Applications as Part of the ZEISS Medical Ecosystem

Monday, September 20, 2021 - 3:00pm

ZEISS introduces a new integrated cataract workflow solution for lens replacement with the launch of the ZEISS QUATERA 700*.

Key Points: 
  • ZEISS introduces a new integrated cataract workflow solution for lens replacement with the launch of the ZEISS QUATERA 700*.
  • This revolution in phaco technology includes the ZEISS patented QUATTRO Pumpwhich delivers chamber stability independent of intra-ocular pressure (IOP) and flow.
  • The QUATERA 700 increases a surgeon's workflow efficiency from the clinic to the operating room, enabling one digitally integrated surgical workflow.
  • *ZEISS QUATERA 700, ZEISS CT LUCIA 621, ZEISS Surgery Optimizer, ZEISS EYEGUIDE, ZEISS OPTIKIT, ZEISS VISUMAX 800 and ZEISS Refractive Workplace are not available for sale or use in some markets.

ZEISS Introduces a Series of Major Innovations and Industry-First Software Applications as Part of the ZEISS Medical Ecosystem

Monday, September 20, 2021 - 3:00pm

JENA, Germany and DUBLIN, Calif., Sept. 20, 2021 /PRNewswire/ -- At ZEISS Innovation Week, September 21- 23, 2021, ZEISS Medical Technology will introduce industry-first, integrated solutions that bring further value to the ZEISS Medical Ecosystem, connecting devices, data and applications that will help maximize clinical efficiency and performance.

Key Points: 
  • ZEISS introduces a new integrated cataract workflow solution for lens replacement with the launch of the ZEISS QUATERA 700*.
  • This revolution in phaco technology includes the ZEISS patented QUATTRO Pumpwhich delivers chamber stability independent of intra-ocular pressure (IOP) and flow.
  • The ZEISS Cataract Workflow is further enhanced with two new and original surgical software applications.
  • *ZEISS QUATERA 700, ZEISS CT LUCIA 621, ZEISS Surgery Optimizer, ZEISS EYEGUIDE, ZEISS OPTIKIT, ZEISS VISUMAX 800 and ZEISS Refractive Workplace are not available for sale or use in some markets.

Atlas Healthcare Announces Strategic Organizational Appointments

Monday, September 20, 2021 - 3:06pm

"We congratulate Chuck on his new role, and we are pleased to welcome Jason to our leadership team," said Atlas Healthcare Partners CEO Aric Burke.

Key Points: 
  • "We congratulate Chuck on his new role, and we are pleased to welcome Jason to our leadership team," said Atlas Healthcare Partners CEO Aric Burke.
  • Chuck's and Jason's proven success in developing JV partnerships adds to the long-term value Atlas provides to prominent health systems and physicians."
  • Atlas Healthcare Partners specializes in the development and management of ambulatory surgery centers (ASCs).
  • In 2018, Banner Health partnered with Atlas Healthcare Partners to develop, manage, and grow their ASC network.

Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.

Monday, September 20, 2021 - 12:00pm

Demodex-driven meibomian gland dysfunction is characterized by decreased lipid secretion into the tear film and is a leading cause of dry eye disease.

Key Points: 
  • Demodex-driven meibomian gland dysfunction is characterized by decreased lipid secretion into the tear film and is a leading cause of dry eye disease.
  • Under the agreement, Glaukos has the exclusive global right to research, develop, manufacture and commercialize products using certain acetylcholinesterase (AChE) inhibitors for the treatment of ophthalmic diseases caused by Demodex mites.
  • Attillaps lead compounds have demonstrated promising in-vitro results in preclinical settings.
  • This licensing agreement adds a promising therapeutic class that expands the focus of our emerging Corneal Health franchise into new and globally underserved disease indications, said Thomas Burns, Glaukos president and chief executive officer.

Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference

Monday, September 20, 2021 - 12:00pm

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals ,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m.

Key Points: 
  • WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals ,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m.
  • The conference will be held in a virtual meeting format.
  • The event will be available via live webcast from the Events and Presentations page of the Investors and Media section of the companys website at https://investors.apellis.com/events-and-presentations .
  • Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies.

Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition

Monday, September 20, 2021 - 11:30am

Dr. Pacyniak will oversee all aspects of nonclinical toxicology and drug disposition for Aerie.

Key Points: 
  • Dr. Pacyniak will oversee all aspects of nonclinical toxicology and drug disposition for Aerie.
  • He most recently held a related nonclinical safety assessment position at Mycovia Pharmaceuticals, Inc.
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Envision Healthcare Shares Resources to Support Clinician Mental Health

Friday, September 17, 2021 - 4:33pm

Envision Healthcare, a leading national medical group, is providing best practices on how to improve the professional well-being of clinicians and mitigate burnout.

Key Points: 
  • Envision Healthcare, a leading national medical group, is providing best practices on how to improve the professional well-being of clinicians and mitigate burnout.
  • To help the more than 50 percent of clinicians who experience symptoms of burnout,1 Envision is sharing its mental health resources with the entire medical community.
  • We must ensure all clinicians have the resources necessary to support their mental health and well-being.
  • To further support clinician well-being, Envision supports organizational and healthcare system policy improvements, such as improving practice schedule flexibility, reforming tort laws and providing student loan relief.

Tools4Patient Develops Predictive Model of the Placebo Response in Parkinson's Disease

Friday, September 17, 2021 - 3:01pm

"Modeling the Placebo Response in Parkinson's Disease" was presented at the International Parkinson and Movement Disorders Society's MDS Congress 2021.

Key Points: 
  • "Modeling the Placebo Response in Parkinson's Disease" was presented at the International Parkinson and Movement Disorders Society's MDS Congress 2021.
  • The predictive, multivariate Placebell model is based on patients' psychological traits and other factors associated with the placebo response (e.g., baseline PD intensity).
  • "The placebo response is a significant barrier to demonstrating efficacy of experimental therapies for Parkinson's disease," says Olivier Rascol, M.D., Ph.D.
  • "This predictive model of the placebo response in Parkinson's disease is an important step forward in managing this issue and accelerating the delivery of medicines to this patient population."

Global Dry Eye Treatment Devices Market Size, Share & Trends Analysis Report 2021-2028 - ResearchAndMarkets.com

Friday, September 17, 2021 - 2:06pm

The "Global Dry Eye Treatment Devices Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dry Eye Treatment Devices Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global dry eye treatment devices market size is estimated to reach USD 414.2 million by 2028.
  • The increasing number of clinical and research activities conducted to evaluate the safety and efficacy of advanced dry eye treatment devices such as IPL and BBL will boost market growth.
  • Besides, clinical studies of these technologies are showing promising results in comparison with conventional treatment methods in dry eye treatment.